前沿专利观察 / Patent Frontier Watch
第008期：制药前沿：抗体、剂型、给药系统与转化细节
本期重写为逐件研读版，重点看生命科学专利怎样把靶点、递送、组合物、制剂、给药路径和稳定性条件落成可制造的技术方案。
为什么选这些专利
本期选择标准不是随机编号，也不是标题看起来热门，而是每件专利都对应一个可被拆解的工程问题：它必须能说明一个具体痛点，并且在公开文本中给出结构、流程、材料组合、数据处理或控制策略。下面按逐件研读方式展开。
1. High sterol-containing lipid nanoparticles
代表专利：US-12343405-B2。申请人/权利人：NANOVATION THERAPEUTICS INC (CA) NANO VATION THERAPEUTICS INC (CA)。优先权日：2022/03/23；公开日：2025/07/01；授权日：2025/07/01。
它真正发现的问题
这件专利的问题落在“High sterol-containing lipid nanoparticles”对应的药物转化环节：The present disclosure provides a lipid nanoparticle comprising: a nucleic acid cargo molecule; sterol or a derivative thereof present at elevated content; neutral lipid; an ionizable lipid; and a hydrophilic polymer-lipid conjugate present at a content between 0. 研读重点是成分、载体、给药或制备条件如何解决稳定性、递送效率或药效路径问题。
它的技术方案
公开摘要显示，方案的具体构成是：The present disclosure provides a lipid nanoparticle comprising: a nucleic acid cargo molecule; sterol or a derivative thereof present at elevated content; neutral lipid; an ionizable lipid; and a hydrophilic polymer-lipid conjugate present at a content between 0.5 and 3 mol %, wherein each mol % content is relative to total lipid present in the lipid nanoparticle.
给我们的启示
启示是，递送平台布局要覆盖配方比例、制备方法、载荷类型、稳定性指标和用途，而不是只保护一种载荷。
2. Novel bifunctional molecules for targeted protein degradation
代表专利：AU-2021400059-A1。申请人/权利人：AMPHISTA THERAPEUTICS LTD (GB)。优先权日：2020/12/18；公开日：2023/07/06。
它真正发现的问题
这件专利的问题落在“Novel bifunctional molecules for targeted protein degradation”对应的药物转化环节：The present disclosure relates to a novel class of bifunctional molecules that are useful in a targeted or selective degradation of a protein. 研读重点是成分、载体、给药或制备条件如何解决稳定性、递送效率或药效路径问题。
它的技术方案
公开摘要显示，方案的具体构成是：The present disclosure relates to a novel class of bifunctional molecules that are useful in a targeted or selective degradation of a protein.
给我们的启示
启示是，蛋白降解专利要把靶点、E3配体、连接子、细胞内组装和药效结果串起来，形成组合保护。
3. [Translated] Pharmaceutical composition
代表专利：JP-2025078802-A。申请人/权利人：KOWA CO。优先权日：2017/09/01；公开日：2025/05/20。
它真正发现的问题
这件专利的问题落在“[Translated] Pharmaceutical composition”对应的药物转化环节：[Translated] [Problem] To provide a new technology for stably formulating pitavastatin or a salt thereof, or a solvate thereof. 研读重点是成分、载体、给药或制备条件如何解决稳定性、递送效率或药效路径问题。
它的技术方案
公开摘要显示，方案的具体构成是：[Translated] [Problem] To provide a new technology for stably formulating pitavastatin or a salt thereof, or a solvate thereof. [Solution] A pharmaceutical composition containing the following components (A) and (B): (A) pitavastatin or a salt thereof, or a solvate thereof; and (B) ezetimibe or a salt thereof, or a solvate thereof. [Selected Figure] None
给我们的启示
启示是，药物组合物专利的价值在可重复产品条件：配比、剂型、给药路径、稳定性数据和适应症选择需要相互支撑。
4. Lipid nanoparticles for delivery of nucleic acids
代表专利：WO-2021123332-A1。申请人/权利人：CUREVAC AG (DE)。优先权日：2019/12/20；公开日：2021/06/24。
它真正发现的问题
这件专利的问题落在“Lipid nanoparticles for delivery of nucleic acids”对应的药物转化环节：The application relates to cationic lipids and to compositions comprising said cationic lipids useful for the delivery of nucleic acids into living cells. 研读重点是成分、载体、给药或制备条件如何解决稳定性、递送效率或药效路径问题。
它的技术方案
公开摘要显示，方案的具体构成是：The application relates to cationic lipids and to compositions comprising said cationic lipids useful for the delivery of nucleic acids into living cells.
给我们的启示
启示是，递送平台布局要覆盖配方比例、制备方法、载荷类型、稳定性指标和用途，而不是只保护一种载荷。
5. A treatment for patients with mood disorders using n-ethyl-2-(5-fluoro-1h-indol-3-yl)- n-methylethan-1-amine or a pharmaceutically acceptable salt thereof
代表专利：WO-2025111597-A1。申请人/权利人：GILGAMESH PHARMACEUTICALS INC (US)。优先权日：2023/11/22；公开日：2025/05/30。
它真正发现的问题
这件专利的问题落在“A treatment for patients with mood disorders using n-ethyl-2-(5-fluoro-1h-indol-3-yl)- n-methylethan-1-amine or a pharmaceutically acceptable salt thereof”对应的药物转化环节：The present disclosure relates to a method of treating a patient having a mood disorder comprising administering to a subject in need thereof a pharmaceutical composition comprising a base compound comprising substantially pure N-ethyl-2-(5-fluoro-1H-indol-3-yl)-N-methylethan-1-amine or a pharmaceutically acceptable salt thereof in a specific dosing regimen. 研读重点是成分、载体、给药或制备条件如何解决稳定性、递送效率或药效路径问题。
它的技术方案
公开摘要显示，方案的具体构成是：The present disclosure relates to a method of treating a patient having a mood disorder comprising administering to a subject in need thereof a pharmaceutical composition comprising a base compound comprising substantially pure N-ethyl-2-(5-fluoro-1H-indol-3-yl)-N-methylethan-1-amine or a pharmaceutically acceptable salt thereof in a specific dosing regimen.
给我们的启示
启示是，药物组合物专利的价值在可重复产品条件：配比、剂型、给药路径、稳定性数据和适应症选择需要相互支撑。
6. Methods of preparing lipid nanoparticles
代表专利：EP-4427739-A2。申请人/权利人：MODERNATX INC (US)。优先权日：2019/01/31；公开日：2024/09/11。
它真正发现的问题
这件专利的问题落在“Methods of preparing lipid nanoparticles”对应的药物转化环节：The present disclosure provides methods of producing lipid nanoparticle (LNP) formulations and the produced LNP formulations thereof. 研读重点是成分、载体、给药或制备条件如何解决稳定性、递送效率或药效路径问题。
它的技术方案
公开摘要显示，方案的具体构成是：The present disclosure provides methods of producing lipid nanoparticle (LNP) formulations and the produced LNP formulations thereof. The present disclosure also provides therapeutic and diagnostic uses related to the produced LNP formulations.
给我们的启示
启示是，递送平台布局要覆盖配方比例、制备方法、载荷类型、稳定性指标和用途，而不是只保护一种载荷。
7. N/O-linked degrons and degronimers for protein degradation
代表专利：US-12180225-B2。申请人/权利人：C4 THERAPEUTICS INC (US)。优先权日：2017/06/20；公开日：2024/12/31；授权日：2024/12/31。
它真正发现的问题
这件专利的问题落在“N/O-linked degrons and degronimers for protein degradation”对应的药物转化环节：This invention provides Degronimers that have E3 Ubiquitin Ligase targeting moieties (Degrons) that can be linked to a targeting ligand for a protein that has been selected for in vivo degradation, and methods of use and compositions thereof as well as methods for their preparation. 研读重点是成分、载体、给药或制备条件如何解决稳定性、递送效率或药效路径问题。
它的技术方案
公开摘要显示，方案的具体构成是：This invention provides Degronimers that have E3 Ubiquitin Ligase targeting moieties (Degrons) that can be linked to a targeting ligand for a protein that has been selected for in vivo degradation, and methods of use and compositions thereof as well as methods for their preparation. The invention also provides Degrons that can be used to treat disorders mediated by cereblon or an Ikaros family protein, and methods of use and compositions thereof as well as methods for their preparation.
给我们的启示
启示是，蛋白降解专利要把靶点、E3配体、连接子、细胞内组装和药效结果串起来，形成组合保护。
8. Pharmaceutical composition for oral administration of edaravone and method of administering same
代表专利：US-12310946-B2。申请人/权利人：MITSUBISHI TANABE PHARMA CORP (JP)。优先权日：2020/11/12；公开日：2025/05/27；授权日：2025/05/27。
它真正发现的问题
这件专利的问题落在“Pharmaceutical composition for oral administration of edaravone and method of administering same”对应的药物转化环节：A method of treating an oxidative stress disease includes orally or intragastrically administering, to a subject in need thereof, a pharmaceutical composition including edaravone with a time interval from a consumption of a meal by the subject in need thereof to an administration of the pharmaceutical composition to the subject in need thereof. 研读重点是成分、载体、给药或制备条件如何解决稳定性、递送效率或药效路径问题。
它的技术方案
公开摘要显示，方案的具体构成是：A method of treating an oxidative stress disease includes orally or intragastrically administering, to a subject in need thereof, a pharmaceutical composition including edaravone with a time interval from a consumption of a meal by the subject in need thereof to an administration of the pharmaceutical composition to the subject in need thereof. The time interval is 8 hours or longer after the consumption of a high-fat meal, the time interval is 4 hours or longer after the consumption of a standard meal, or the tim...
给我们的启示
启示是，药物组合物专利的价值在可重复产品条件：配比、剂型、给药路径、稳定性数据和适应症选择需要相互支撑。
9. Lipid nanoparticles for delivery of agents
代表专利：US-2025049713-A1。申请人/权利人：MASSACHUSETTS INST TECHNOLOGY (US) FUJIFILM CORP (JP)。优先权日：2023/04/13；公开日：2025/02/13。
它真正发现的问题
这件专利的问题落在“Lipid nanoparticles for delivery of agents”对应的药物转化环节：The present disclosure provides compositions which enable the delivery of cargo, including therapeutic agents such as RNA, to organs or tissues in addition to the liver, lungs, and spleen, such as brain, heart, kidney, and muscle tissue. 研读重点是成分、载体、给药或制备条件如何解决稳定性、递送效率或药效路径问题。
它的技术方案
公开摘要显示，方案的具体构成是：The present disclosure provides compositions which enable the delivery of cargo, including therapeutic agents such as RNA, to organs or tissues in addition to the liver, lungs, and spleen, such as brain, heart, kidney, and muscle tissue. More specifically, the compositions comprise a plurality of lipid particles comprising an agent, cationic lipids and ionizable lipid.
给我们的启示
启示是，递送平台布局要覆盖配方比例、制备方法、载荷类型、稳定性指标和用途，而不是只保护一种载荷。
10. N/O-linked degrons and degronimers for protein degradation
代表专利：US-12441740-B2。申请人/权利人：C4 THERAPEUTICS INC (US)。优先权日：2017/06/20；公开日：2025/10/14；授权日：2025/10/14。
它真正发现的问题
这件专利的问题落在“N/O-linked degrons and degronimers for protein degradation”对应的药物转化环节：This invention provides Degronimers that have E3 Ubiquitin Ligase targeting moieties (Degrons) that can be linked to a targeting ligand for a protein that has been selected for in vivo degradation, and methods of use and compositions thereof as well as methods for their preparation. 研读重点是成分、载体、给药或制备条件如何解决稳定性、递送效率或药效路径问题。
它的技术方案
公开摘要显示，方案的具体构成是：This invention provides Degronimers that have E3 Ubiquitin Ligase targeting moieties (Degrons) that can be linked to a targeting ligand for a protein that has been selected for in vivo degradation, and methods of use and compositions thereof as well as methods for their preparation. The invention also provides Degrons that can be used to treat disorders mediated by cereblon or an Ikaros family protein, and methods of use and compositions thereof as well as methods for their preparation.
给我们的启示
启示是，蛋白降解专利要把靶点、E3配体、连接子、细胞内组装和药效结果串起来，形成组合保护。
11. Vigabatrin liquid pharmaceutical composition
代表专利：US-12290499-B2。申请人/权利人：PYROS PHARMACEUTICALS INC (US)。优先权日：2022/09/16；公开日：2025/05/06；授权日：2025/05/06。
它真正发现的问题
这件专利的问题落在“Vigabatrin liquid pharmaceutical composition”对应的药物转化环节：The embodiments of the present invention relate to a stable liquid vigabatrin pharmaceutical compositions in the liquid form of a solution. 研读重点是成分、载体、给药或制备条件如何解决稳定性、递送效率或药效路径问题。
它的技术方案
公开摘要显示，方案的具体构成是：The embodiments of the present invention relate to a stable liquid vigabatrin pharmaceutical compositions in the liquid form of a solution. Particularly, the stable vigabatrin liquid pharmaceutical composition is manufactured as a ready-to-use industrialized premixture that does not require reconstitution or dilution prior to administration to a patient. The vigabatrin liquid pharmaceutical composition is stable six months or longer at room temperature and has levels of total impurities and Vigabatrin-related comp...
给我们的启示
启示是，药物组合物专利的价值在可重复产品条件：配比、剂型、给药路径、稳定性数据和适应症选择需要相互支撑。
12. [Translated] lipid nanoparticles
代表专利：IL-294624-A。申请人/权利人：ETHERNA IMMUNOTHERAPIES NV (BE) UNIV BRUSSEL VRIJE (BE) DE KOKER STEFAAN BEVERS SANNE SCHIFFELERS RAYMOND MICHEL KOOIJMANS SANDER ALEXANDER ANTONIUS。优先权日：2020/01/21；公开日：2022/09/01。
它真正发现的问题
LNP药物递送的核心问题是载荷、脂质组成、粒径、稳定性和体内分布之间的平衡。若只改变核酸或药物本身，未必能获得可制造、可储存和可转化的递送体系。
它的技术方案
该条目围绕脂质纳米颗粒，重点应读离子化脂质、辅助脂质、胆固醇/PEG脂质等载体组成，以及其对核酸或药物包封、稳定性和递送效率的影响。
给我们的启示
启示是，LNP专利布局要形成“脂质组成-制备条件-载荷类型-用途”的矩阵，不能只围绕单一成分。
13. Pharmaceutical compositions of spironolactone for deep dermal drug delivery
代表专利：US-12458652-B2。申请人/权利人：ARCUTIS BIOTHERAPEUTICS INC (US)。优先权日：2021/11/11；公开日：2025/11/04；授权日：2025/11/04。
它真正发现的问题
这件专利的问题落在“Pharmaceutical compositions of spironolactone for deep dermal drug delivery”对应的药物转化环节：Pharmaceutical compositions for the topical administration of spironolactone to the pilosebaceous unit and methods for administering the same. 研读重点是成分、载体、给药或制备条件如何解决稳定性、递送效率或药效路径问题。
它的技术方案
公开摘要显示，方案的具体构成是：Pharmaceutical compositions for the topical administration of spironolactone to the pilosebaceous unit and methods for administering the same. The pharmaceutical compositions comprise aqueous suspensions of submicron particles of spironolactone in water.
给我们的启示
启示是，药物组合物专利的价值在可重复产品条件：配比、剂型、给药路径、稳定性数据和适应症选择需要相互支撑。
14. [Translated] SiRNA for regulating and controlling AGT gene expression and application thereof
代表专利：CN-119040330-B。申请人/权利人：公开页面未列明。优先权日：2024/11/01；公开日：2025/03/04；授权日：2025/03/04。
它真正发现的问题
这件专利的问题落在“[Translated] SiRNA for regulating and controlling AGT gene expression and application thereof”对应的药物转化环节：[Translated] The present disclosure provides an siRNA that modulates AGT gene expression and uses thereof. 研读重点是成分、载体、给药或制备条件如何解决稳定性、递送效率或药效路径问题。
它的技术方案
公开摘要显示，方案的具体构成是：[Translated] The present disclosure provides an siRNA that modulates AGT gene expression and uses thereof. The siRNA has obvious inhibition effect on AGT gene expression in cell experiments, and can be used for developing medicaments for treating and/or preventing diseases related to AGT gene expression.
给我们的启示
启示是，递送平台布局要覆盖配方比例、制备方法、载荷类型、稳定性指标和用途，而不是只保护一种载荷。
15. Lipid nanoparticle compositions for delivery of mRNA and long nucleic acids
代表专利：US-12357580-B2。申请人/权利人：UNIV TEXAS (US)。优先权日：2018/06/19；公开日：2025/07/15；授权日：2025/07/15。
它真正发现的问题
这件专利的问题落在“Lipid nanoparticle compositions for delivery of mRNA and long nucleic acids”对应的药物转化环节：In some aspects, the present disclosure provides compositions of lipid nanoparticles useful for the delivery of large RNAs including mRNAs. 研读重点是成分、载体、给药或制备条件如何解决稳定性、递送效率或药效路径问题。
它的技术方案
公开摘要显示，方案的具体构成是：In some aspects, the present disclosure provides compositions of lipid nanoparticles useful for the delivery of large RNAs including mRNAs. These compositions may include a cationic ionizable lipid, a phospholipid, a PEGylated lipid, and a steroid including using less of a cationic ionizable lipid than compositions with shorter nucleic acids. These compositions may be used to treat a disease or disorder for which the delivery of an mRNA is therapeutically effective.
给我们的启示
启示是，递送平台布局要覆盖配方比例、制备方法、载荷类型、稳定性指标和用途，而不是只保护一种载荷。
16. Cd20-targeted antibody coupling pharmaceutical preparation
代表专利：US-2025269049-A1。申请人/权利人：ZHEJIANG TERUISI PHARMACEUTICAL INC (CN)。优先权日：2017/02/20；公开日：2025/08/28。
它真正发现的问题
这件专利的问题落在“Cd20-targeted antibody coupling pharmaceutical preparation”对应的药物转化环节：Provided is a CD20-targeted antibody-drug conjugate and a pharmaceutical composition comprising thereof, as well a method for preparing the same. 研读重点是成分、载体、给药或制备条件如何解决稳定性、递送效率或药效路径问题。
它的技术方案
公开摘要显示，方案的具体构成是：Provided is a CD20-targeted antibody-drug conjugate and a pharmaceutical composition comprising thereof, as well a method for preparing the same. The antibody-drug conjugate of the present invention has a specific DAR component distribution optimized for drug loading, and is produced by accurately controlling the feed ratio. The antibody-drug conjugate of the present invention has excellent drug activity, good stability, low toxicity and good drug development properties.
给我们的启示
启示是，药物组合物专利的价值在可重复产品条件：配比、剂型、给药路径、稳定性数据和适应症选择需要相互支撑。
本期结论
这些制药专利共同说明，药物专利的价值常在转化细节：递送载体、组合比例、制备条件、给药方式和稳定性指标决定了发明能否从机理走向产品。
资料来源 / Sources
本期依据 PubChem patent JSON、Google Patents 公开页面和原公开链接研读整理。正式FTO或授权稳定性判断仍需进一步核对官方登记簿、审查历史、同族和权利要求全文。
- US-12343405-B2 - High sterol-containing lipid nanoparticles
- AU-2021400059-A1 - Novel bifunctional molecules for targeted protein degradation
- JP-2025078802-A - [Translated] Pharmaceutical composition
- WO-2021123332-A1 - Lipid nanoparticles for delivery of nucleic acids
- WO-2025111597-A1 - A treatment for patients with mood disorders using n-ethyl-2-(5-fluoro-1h-indol-3-yl)- n-methylethan-1-amine or a pharmaceutically acceptable salt thereof
- EP-4427739-A2 - Methods of preparing lipid nanoparticles
- US-12180225-B2 - N/O-linked degrons and degronimers for protein degradation
- US-12310946-B2 - Pharmaceutical composition for oral administration of edaravone and method of administering same
- US-2025049713-A1 - Lipid nanoparticles for delivery of agents
- US-12441740-B2 - N/O-linked degrons and degronimers for protein degradation
- US-12290499-B2 - Vigabatrin liquid pharmaceutical composition
- IL-294624-A - [Translated] lipid nanoparticles
- US-12458652-B2 - Pharmaceutical compositions of spironolactone for deep dermal drug delivery
- CN-119040330-B - [Translated] SiRNA for regulating and controlling AGT gene expression and application thereof
- US-12357580-B2 - Lipid nanoparticle compositions for delivery of mRNA and long nucleic acids
- US-2025269049-A1 - Cd20-targeted antibody coupling pharmaceutical preparation